Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast...

Area of Science:

• Biomedical Science
• Oncology
• Drug Development

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 receptors, leading to higher relapse rates.
• Developing targeted therapies is crucial for improving TNBC treatment outcomes.
• Current treatment options for TNBC are limited, necessitating novel therapeutic strategies.

Purpose of the Study:

• To develop and evaluate a novel aptamer-drug conjugate (ApDC) for targeted TNBC therapy.
• To assess the efficacy and specificity of the AS1411-triptolide conjugate (ATC) against TNBC.
• To investigate the in vivo performance and safety profile of ATC.

Main Methods:

• Synthesis and characterization of the AS1411-triptolide conjugate (ATC).
• In vitro cytotoxicity assays using the MDA-MB-231 TNBC cell line.
• In vivo studies to evaluate anti-tumor efficacy and assess side effects in relevant models.

Main Results:

• The developed ATC exhibited high specificity and potent cytotoxicity against the MDA-MB-231 TNBC cell line.
• In vivo studies demonstrated excellent efficacy of ATC in combating TNBC.
• ATC showed negligible side effects on healthy organs, indicating a favorable safety profile.

Conclusions:

• The novel aptamer-drug conjugate, ATC, represents a promising targeted therapy for triple-negative breast cancer.
• ATC demonstrates high efficacy and specificity, offering a potential new treatment avenue for TNBC.
• The favorable in vivo profile suggests ATC could be a safe and effective therapeutic option for TNBC patients.